Clinical Trial Update: Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating sorafenib with letrozole, anastrozole, or exemestane in postmenopausal women with ER-positive and/or PR-positive metastatic breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Aromasin (exemestane)
• FEMARA (letrozole)
• Nexavar (Sorafenib)

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-03-26